Disulfiram: New support for an old addiction drug

January 31, 2013

Disulfiram was the first medication approved for the treatment of alcoholism over 50 years ago. It works, at least in part, by preventing the metabolism of an alcohol by-product, acetaldehyde. High levels of acetaldehyde in the body quickly cause unpleasant symptoms, including nausea, vomiting, headache, and accelerated heart rate. Thus, disulfiram provides a very strong incentive to avoid drinking.

Beginning in the late 1990s, a series of studies conducted at Yale University found that disulfiram reduced the consumption of cocaine, particularly in the context of or opiate dependence. One mechanism introduced to explain this phenomenon was the ability of disulfiram to inhibit dopamine β-hydroxylase, or DβH, an enzyme that converts dopamine to norepinephrine. This hypothesis was supported in a new pharmacogenetic study by Thomas Kosten and colleagues, published in Biological Psychiatry.

The researchers recruited cocaine- and opioid-dependent patients who were randomized to receive either disulfiram or placebo for ten weeks. They also genotyped the DBH gene, which alters DβH levels, to determine which variant that each patient carried. Prior work has already shown that individuals with the CC genotype have normal DβH levels, whereas those carrying the T allele have lower DβH levels. This allowed them to determine whether the functional DBH variant influences the success of disulfiram treatment.

Disulfiram was effective in reducing in patients with the CC genotype and normal DβH levels, whereas those with the low DβH level T genotype showed no disulfiram effect. These data support the hypothesis that disulfiram reduces , in part, by blocking DβH.

Senior author David Nielsen at Baylor College of Medicine said, "We found significantly greater efficacy in who carried a genetic variant of the dopamine β-hydroxylase gene that codes for an enzyme with 10 to 100 fold greater enzyme expression and occurs in about 60% of addicts. Thus, pharmacogenetic matching is critical for the optimal efficacy of disulfiram in cocaine addiction, and this matching includes the majority of these patients."

Disulfiram is not an FDA-approved treatment for cocaine addiction, and in fact, there are currently no approved medications to treat cocaine addiction.

"Cocaine has proven to be a particularly difficult challenge from the perspective of medication development. No doubt this reflects the powerful control that cocaine and cocaine-related cues exert on behavior. However, the current study suggests that pharmacogenetic approaches might be a strategy to match medications like disulfiram to patients who would be more likely to respond," commented Dr. John Krystal, Editor of .

Explore further: Treating cocaine dependence: A promising new pharmacotherapy

More information: The article is "Pharmacogenetic Randomized Trial for Cocaine Abuse: Disulfiram and Dopamine β-Hydroxylase" by Thomas R. Kosten, Guiying Wu, Wen Huang, Mark J. Harding, Sara C. Hamon, Jaakko Lappalainen, and David A. Nielsen (doi: 10.1016/j.biopsych.2012.07.011). The article appears in Biological Psychiatry, Volume 73, Issue 3 (February 1, 2013)

Related Stories

Treating cocaine dependence: A promising new pharmacotherapy

November 28, 2012

Medication development efforts for cocaine dependence have yet to result in an FDA approved treatment. The powerful rewarding effects of cocaine, the profound disruptive impact of cocaine dependence on one's lifestyle, and ...

Treatment for cocaine addiction targets relapse

January 15, 2013

(Medical Xpress)—What is the best intervention window for someone struggling with cocaine addiction? When he or she is in the middle of a drug binge, or after a period of abstinence when there is temptation to fall back ...

Recommended for you

Serious research into what makes us laugh

November 24, 2015

More complex jokes tend to be funnier but only up to a point, Oxford researchers have found. Jokes that are too complicated tend to lose the audience.

Psychologists dispute continuum theory of sexual orientation

November 19, 2015

Washington State University researchers have established a categorical distinction between people who are heterosexual and those who are not. By analyzing the reported sexual behavior, identity and attraction of more than ...

Babies have logical reasoning before age one, study finds

November 18, 2015

Human infants are capable of deductive problem solving as early as 10 months of age, a new study by psychologists at Emory University and Bucknell finds. The journal Developmental Science is publishing the research, showing ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.